Clinical Trials on Meningitis, Meningococcal in United Kingdom

Total 222 results

Prof. Elizabeth Miller
Novartis Vaccines

Completed

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults (MenOccy)

Meningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup W

United Kingdom
Chiron Corporation

Unknown

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Meningococcal Disease; Meningococcal Meningitis

United Kingdom
Public Health England

Completed

Comparison of Two Meningococcal ACWY Conjugate Vaccines (PRIME)

Meningococcal Meningitis

United Kingdom
University of Oxford

Completed

Investigating Meningococcal Vaccines in Adults

Meningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria Meningitidi

United Kingdom
University Hospital Southampton NHS Foundation...
University of Southampton

Unknown

A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14 (Lac-3)

Meningitis, Meningococcal

United Kingdom
Belfast Health and Social Care Trust
Queen's University, Belfast; Royal College of Emergency Medicine; Pediatric Emergency... and other collaborators

Completed

Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. (PIC)

Sepsis | Meningitis, Meningococcal | Meningitis | Meningococcal Infections | Meningococcal Disease | Meningococcal Sepsis

United Kingdom
Novartis Vaccines

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Meningococcal Disease | Meningococcal Meningitis

Spain, Italy, United Kingdom, Czech Republic
St George's, University of London

Unknown

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive)

HIV Infections | Hiv | Meningitis, Meningococcal

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Novartis Vaccines
Novartis

Completed

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Meningococcal Disease | Meningococcal Meningitis

United States
JN-International Medical Corporation

Completed

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Meningococcal Disease | Meningococcal Meningitis

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

United States
Sanofi

Completed

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
University of Oxford

Active, not recruiting

Sero-epidemiological Survey of England in 2019/2020 - COVID-19 (STORY)

COVID-19 | Diphtheria | Serogroup C Meningococcal Meningitis

United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
JN-International Medical Corporation

Completed

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Public Health England

Withdrawn

Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock (Lock and Key)

Meningitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Dose Comparison Study of Menactra® in US Children

Meningitis | Meningococcal Infection | Neisseria Meningitidis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
JN-International Medical Corporation

Completed

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis
Novartis Vaccines

Completed

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Meningococcal Meningitis

United States, Italy
University of Oxford

Completed

Understanding the Immune Response to Two Different Meningitis Vaccines

Meningitis | Meningococcal Disease | Septicaemia

United Kingdom
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
GlaxoSmithKline

Active, not recruiting

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Meningitis, Meningococcal

Germany, United States
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Meningitis | Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Meningitis | Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Chile
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
University of Oxford
GlaxoSmithKline; Oxford University Hospitals NHS Trust

Completed

Can we Reduce the Number of Vaccine Injections for Children? (MALTA)

Invasive Meningococcal Disease

United Kingdom
QIAGEN Gaithersburg, Inc

Completed

QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study

Meningitis/Encephalitis

United Kingdom
University of Oxford
Norwegian Institute of Public Health; Wellcome Trust

Completed

MenPF-1 - A New Vaccine Against Meningococcal Disease

Serogroup B Meningococcal Disease

United Kingdom

Clinical Trials on Meningitis, Meningococcal in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations